Join
Live feed
·
PRReleasevia Quantisnow
Immunomedics, Inc. logo

Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer

ByQuantisnow·Wall Street's wire, on your screen.
Full content unavailable. See the original source below.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track IMMU (Immunomedics, Inc.) and more on Quantisnow.